Newsletter

290650 - L & C BIO Co., Ltd.

290650 Summary
Biopharma
Stock Price & Overview
₩47,900 -700 (-1.44%) Close · Sep 4, 2026 KST
KOSDAQ | ₩KRW | Close: ₩47,900  ≈ US$34  ·  Market cap ₩1.3tn (≈ $923m)
Why this page exists. Korean issuers file to DART, not the SEC, and almost nothing is published in English. Titles here are translated; where kstock has read the filing, the row carries the explanation and the amount in won and dollars. How we pick »

290650 DART Filings

DART

Ex-rights

Filing09/02/26title translated
DART

Prospectus

Filing09/02/26title translated
DART

Securities registration statement (equity securities)

Filing09/02/26title translated
DART

Paid-in and bonus share issue

Filing09/02/26title translated
DART

Rights offering: first issue price determined

Filing09/02/26title translated
DART

Notice that the registration statement has taken effect

Filing09/02/26title translated
DART

Securities registration statement (equity securities)

Filing08/31/26title translated
DART

Securities registration statement (equity securities)

Filing08/18/26title translated
DART

Half-Year Report

Periodic08/14/26title translated
DART

Trading plan report by an officer or major shareholder

Filing08/11/26title translated
DART

Loss Incurred on Derivatives Trading

Derivatives08/11/26title translated
DART

Preliminary Consolidated Results (Fair Disclosure)

Earnings08/11/26title translated
DART

Preliminary operating results (fair disclosure)

Filing08/11/26title translated
DART

Securities registration statement (equity securities)

Filing08/03/26title translated
DART

Share trading halt (bonus issue)

Filing07/31/26title translated
DART

Paid-in and bonus share issue

Filing07/31/26title translated
DART

Audit report submitted

Filing06/12/26title translated
DART

Appointment, dismissal or early departure of an independent director

Filing05/29/26title translated
DART

Quarterly Report

Periodic05/15/26title translated
DART

Preliminary operating results (fair disclosure)

Filing05/11/26title translated
DART

Preliminary Consolidated Results (Fair Disclosure)

Earnings05/11/26title translated
5 routine filings (insider holdings reports, IR schedules)DART

Insider / Major Shareholder Holdings Report

Ownership08/12/26title translated
DART

5% Ownership Report — Large Holdings

Ownership06/23/26title translated
DART

5% Ownership Report — Short Form

Ownership06/10/26title translated
DART

Insider / Major Shareholder Holdings Report

Ownership06/05/26title translated
DART

5% Ownership Report — Short Form

Ownership06/05/26title translated
26 filings on file, grouped where one event produced many. Source: DART, operated by Korea's Financial Supervisory Service.

Similar to 290650

SymbolLast Price
007390Naturecell Co., Ltd.₩23,950
+0.2%
006280GC Biopharma Corp.₩127,600
+0.5%
950160Kolon Tissue Gene, Inc.₩17,100
+1.1%
039200Oscotec, Inc.₩36,600
+1.9%
069620Daewoong Pharma₩116,100
+1.1%
127120JS Link₩33,600
+12.4%
475830Orum Therapeutics, Inc.₩55,900
+2.6%
195940HK inno.N Corporation₩42,050
+0.7%
003090Daewoong Co., Ltd.₩16,860
-2.0%
086450Dong Kook Pharmaceutical Co., Ltd.₩21,600
-0.9%
Compare all 48 in Biopharma

What a US investor should know

  • Trading hours09:00–15:30 KST — 20:00–02:30 US Eastern the night before.
  • Daily limitKorean stocks can move at most ±30% in a session before trading halts.
  • Getting exposureKRX shares are not directly tradable in most US brokerage accounts. The usual routes are Korea ETFs or an international account.
  • ReportingKorean issuers file to DART, not the SEC. Half-year and quarterly reports land about 45 days after period end.